Novye Izvestia has already reported on the main event of recent times: the pharmaceutical company Pfizer will produce an effective drug for covid. The company has published preliminary results from a study of 775 adults who took 30 tablets for 5 days. Halfway through the study, an independent committee advised Pfizer to seek approval for the drug in the US and other regulators.
Patients who received paxlovid shortly after their onset of COVID-19 had an 89% decrease in hospital admissions or deaths after one month compared to those who took the pacifier. Less than 1% required hospitalization and no one died.
By the end of the year, Pfizer is going to produce over 180,000 packages. The company is working to increase production to at least 50 million packs in 2022.
Similar tablets - molnupiravir - were developed by the Merck concern. However, the effectiveness of these tablets is significantly lower and amounted to 50%. In April, the manufacturer announced voluntary licensing agreements with generic manufacturers in India to accelerate the availability of molnupiravir in over 100 countries.
Economist Nikita Krichevsky has calculated that the preliminary price for a five-day course of both drugs will be $ 700, or about 50 thousand rubles. Affordable money for poor Russia, choking on oil and gas windfall profits.
In order to practically guaranteed to save 1 million sick people, only 50 billion rubles will be required, 2 million - respectively, 100 billion. The budget is planned in the amount of 25 trillion rubles.